See the Glossary for more terms.
Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.
NB: Council approval does not guarantee that a concept will become an initiative.
For the published request for applications, see the June 4, 2014, Guide announcement, Integrated Preclinical/Clinical Program for HIV Topical Microbicides and Biomedical Prevention (IPCP-MBP) (U19).
Request for Applications
Contact: David Burns
Description: Applications may include phylogenetic studies, social and sexual network analyses, mathematical modeling, and studies to examine the acceptability and feasibility of new prevention interventions in the populations and settings identified. Research projects that integrate multiple approaches to achieve these objectives will be strongly encouraged. Mathematical modeling may be proposed to augment phylogenetic and network studies, as well as to examine the potential impact of new interventions. Applications will address the following objectives:
Contact: Vanessa Elharrar
Objective: This initiative seeks to provide a means to determine adherence to HIV treatment or prevention regimens. This will in turn support clinical trials of antiretroviral (ARV)-based prevention and treatment interventions that might otherwise be compromised by nonadherence.
Description: This initiative will support the development of bioanalytical tools and novel approaches that allow clinicians and researchers to provide people with timely feedback on adherence to ARV-based HIV treatment and prevention strategies.
For the published program announcement reviewed in an institute, see the November 20, 2014, Guide announcement, Targeting Persistent HIV Reservoirs (TaPHIR) (R21/R33).
For the published request for applications, see the July 16, 2014, Guide announcement, U.S.-China Program for Research Toward a Cure for HIV/AIDS (R01).
For the published broad agency announcement, see the September 12, 2014, solicitation, Staged Vaccine Development.
Program Announcement Reviewed in an Institute
Contact: Alan Schultz
Objective: This initiative will support multidisciplinary integrated projects that focus on HIV/AIDS prophylactic vaccine discovery research, including nonhuman primate (NHP) studies. Projects will have advanced past the exploratory stage and address the design and development and/or evaluation of an efficacious HIV/AIDS prophylactic vaccine.
Description: The HIVRAD program funds five-year projects that address the design of an efficacious HIV/AIDS prophylactic vaccine. Applications include plans that have advanced past the exploratory stage and include preliminary data. Applications may address the following areas of interest:
This renewal is being modified to also allow for support of translational research of HIV prophylactic vaccine projects at the latter stages of a hypothesis-driven HIVRAD project. Manufacturing is not supported. Examples of later stage translational research can include:
Contact: Richard Hafner
Objective: Tuberculosis infection-resistant individuals (TIRI) are those who do not develop active or latent Mycobacterium tuberculosis (MTB) infection despite heavy exposure to the pathogen. The objective of this initiative is to characterize the genetic, epigenetic, and immunological correlates of protection against TB infection in these individuals in the context of HIV infection.
Description: This initiative will support studies leading to a better understanding of the host factors determining resistance to TB infection and the effect of HIV coinfection. Specifically, this initiative will support studies examining the immunologic correlates of resistance to TB infection among individuals meeting the criteria for being TIRI. Evaluations may include identifying underlying immunogenetic/epigenetic factors, as well as characteristics of the innate immune system and related regulatory genes and signaling pathways that play a role in protection from latent TB infection. Multidisciplinary collaboration using advanced methodologies will be encouraged, incorporating clinical studies coupled with mechanistic experiments using samples and data from well-defined cohorts.
For the published program announcement reviewed in an institute, see the August 29, 2014, Guide announcement, Limited Competition: Strategic Timing of Antiretroviral Treatment (START) (UM1).
For the published request for proposals, see the August 15, 2014, Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals.
Last Updated November 20, 2014
Last Reviewed November 20, 2014